Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genomatica Raises Funds, Drops IPO
by Melody M. Bomgardner
August 6, 2012
| A version of this story appeared in
Volume 90, Issue 32
Biobased chemicals firm Genomatica has raised $41.5 million in a fourth round of funding from new investor Versalis, the chemical arm of Italy’s Eni, as well as existing venture capital investors. At the same time, Genomatica has withdrawn its August 2011 filing with the Securities & Exchange Commission for an initial public offering of stock. It plans instead to commercialize its first products with the help of strategic partners and private investors. Genomatica’s technology uses genetically modified Escherichia coli to produce chemicals, including butanediol and butadiene, from sugar.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter